



January 6, 2012

Jay Williamson
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, DC 20549

**Re: VolitionRX Limited
Form 8-K
Filed October 13, 2011
File No. 000-30402
Form 8-K/A
Filed November 1, 2011**

Dear Mr. Williamson:

VolitionRX Limited, a Delaware corporation (the "Company"), has received and reviewed your letter of November 23, 2011 (the "Comment Letter"), pertaining to the Company's Form 8-K (the "Filing") filed October 13, 2011 and the Company's Form 8-K/A filed November 1, 2011 with the Securities & Exchange Commission (the "Commission").

Per my discussion today with Brian McAllister, we hope to submit our written reply to the Commission no later than January 11, 2012, as the Company is still in the process of reviewing the financial statements and notes to the financial statements in response to the Comment Letter. Again, we apologize for the delay in responding to the Comment Letter.

In connection with the comments in your letter, we acknowledge that:

- The Company is responsible for the adequacy and accuracy of the disclosure in the filing;
- Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
- The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Again, we apologize for our delay. Please do not hesitate to contact us if you have any questions or comments in regard to this letter or the information contained herein.

Very truly yours,

VolitionRX Limited

/s/ Cameron Reynolds

Cameron Reynolds
President and Chief Executive Officer

150 Orchard Road
Orchard Plaza 08-02
Singapore 238841